clinician to detect possible relapse in patients if TK1 levels start to increase.
The TEL-TRKC gene fusion associated with the t(12;15)(p13;q25) translocation has been implicated in both hematological (acute myeloid leukemia (AML)) 1 and non-hematological malignancies (congenital fibrosarcoma, congenital mesoblastic nephroma and secretory breast carcinoma). In AML, the TEL-TRKC (TEL-TRKC(L)) derives from the in-frame fusion of exons 1-4 of TEL to exons 13-18 of TRKC. In contrast, the TEL-TRKC variant associated with solid tumors (TEL-TRKC(F)) contains exons 1-5 of the TEL gene. Activation of both the RAS-MAPK and PI3K-AKT pathways by TEL-TRKC contributes to oncogenic signaling in transfected NIH3T3 cells. 2 However, no human cell lines are available to study the TEL-TRKC fusion.
In this study, we screened over 40 AML cell lines for constitutive phosphorylation of STAT5 by Western blot. The M0-91, an AML-M0-derived cell line 3 , showed constitutive tyrosine phosphorylation of STAT5 (Figure 1a ). To identify protein tyrosine kinases responsible for the constitutive phosphorylation of STAT5 in M0-91, cell lysates were trypsindigested, and phosphopeptides were immunoprecipitated with phosphotyrosine antibody (pY-100), and analyzed by LC-MS/MS mass spectrometry. 4, 5 LC-MS/MS mass spectrometry identified 393 phosphotyrosine sites in 265 proteins (Supplementary Table 1 ). Among these proteins, over 15 tyrosine kinases were tyrosine-phosphorylated (Figure 1b) . Multiple tyrosinephosphorylated peptides corresponded to either TRKB or TRKC, including three tyrosines in the activation loop. Thus, either TRKB or TRKC could be aberrantly activated in M0-91 cells. While full-length TRKB/C have a molecular weight of 140-145 kDa, we observed a 50 kDa by Western blot with a pan-TRK antibody in M0-91 cells (Figure 1c ). In addition, we observed tyrosine-phosphorylated peptides deriving from the TEL protein (Supplementary Table 1 ). TEL is a member of the ETS family transcription factor and is essential for hematopoiesis. It is a frequent target of chromosomal translocations in human cancers, and one of its fusion partners is TRKC.
1 To determine whether a chimeric TEL-TRKC transcript was present, we performed 3 0 rapid amplification of complementary DNA (cDNA) ends on the sequence encoding the HLH domain of TEL. Sequence analysis of the resultant product revealed that the kinase domain of TRKC was fused to TEL gene ( Figure 1d ). In agreement with a previous observation in a patient diagnosed with TEL-TRKC AML, 1 the M0-91 cell line expressed TEL-TRKC fusion transcript (Figure 1e ), with exon 4 of TEL fused in-frame to exon 14 of TRKC. It lacks a 42 bp alternative spliced exon in the TRKC moiety (data not shown). The lack of this exon enhances tyrosine kinase activity.
6,7 Thus, this result confirmed the presence of the 'leukemic' form of the TEL-TRKC fusion. No reciprocal TRKC-TEL fusion gene was detected. The M0-91 cell line did express wild type TEL, but not wild type TRKC (Figure 1e ).
To investigate whether the TEL-TRKC fusion protein contributes to the growth and viability of the M0-91 cells, the expression of the TEL-TRKC fusion was down regulated with an siRNA designed against the TRKC portion of the fusion protein.
Western-blot analysis revealed that the expression of the TEL-TRKC fusion was specifically and significantly reduced at 24 and 48 h following transfection of the TRKC siRNA into M0-91 cells. This is accompanied by a decrease in the phosphorylation of previously known TRKC downstream effectors involving RAS-MAPK, PI3K-AKT and PLCg pathways (AKT, ERK, PLCg1 and PLCg2) (Figure 2a) . For the first time, we Letters to the Editor show that both STAT3 and STAT5 are tyrosine phosphorylated downstream to TEL-TRKC (Figure 2a) , in contrasts to a previous report, where STATs were not activated in TEL-TRKC transformed BaF3 cells. 8 Thus, activation of STATs by TEL-TRKC maybe cell-type specific. Down regulation of TRKC inhibits cell growth (Figure 2b ), and treatment with TRKC siRNA also increases apoptosis of the M0-91 cell line as measured by a cleaved Caspase-3 flow cytometric assay (Figure 2c ). Similar results were observed when M0-91 cells were treated with a relatively selective TRKC inhibitor AG879 (data not shown). These results suggest that the TEL-TRKC fusion is essential for the growth and survival of M0-91 cells. The siRNA knockdown experiments also revealed that phosphorylation of Shc, SHP-2 and SHIP1, as well as expression of both c-Myc and cyclin D1, is regulated by TEL-TRKC fusion (Figure 2d ).
In conclusion, we identified M0-91 as the first cell line expressing the TEL-TRKC fusion gene from its endogenous promoter, and therefore the first valuable cell culture model for the screening for TRKC inhibitors and for understanding both hematological and non-hematological diseases associated with TEL-TRKC. In addition, our phosphoproteomic analysis provided the most comprehensive tyrosine phosphorylation signaling profile reported for TEL-TRKC fusion to date. This information will be useful to develop novel therapeutic approaches for the effective treatment of human cancers associated with deregulated TRKC activity. The CD200 gene (aka MOX-2, OX-2) is located on chromosome 3 and encodes a type-1 membrane glycoprotein. 1 This protein belongs to the immunoglobulin superfamily and is expressed on many different cell types including T and B lymphocytes and dendritic cells.
2 CD200 binds multiple membrane receptor isoforms (CD200R) which have a more tissue restricted expression. 3, 4 The best characterized isoform, CD200R1, has a longer cytoplasmic tail containing three conserved tyrosine residues that can be phosphorylated. 1 These phosphorylated residues interact with signalling adaptor molecules such as Shc, suggesting that the CD200R1 can signal upon binding CD200 ligand providing a more localized response than that provided by cytokines. 5 Although CD200 (À/À) -deficient mice appear grossly normal and live a normal lifespan, they are susceptible to tissue-specific autoimmunity, suggesting that the function of this protein is to induce immune suppression through the CD200R.
6 CD200 also appears to have an alternative role in regulating osteoclast development. 7 In leukaemia, CD200 has been shown to be upregulated in B cells from patients with chronic lymphocytic leukemia. 8 More recently, CD200 has been shown to be an independent prognostic factor for patients with multiple myeloma. 9 In this latter study, expression of CD200 was associated with a bad prognosis. Here we report that in acute myeloid leukaemia (AML), there is a correlation between CD200 expression and the presence of the core binding factor (CBF) associated abnormalities, t(8;21) and inv(16). However, at the same time CD200 expression was linked to worse overall survival in other AML subsets. These data indicate that CD200 is also of prognostic value in AML.
Using a cohort of 184 AML trial patients (all processed and diagnosed at Cardiff as part of the Medical Research Council (MRC) AML Trials), complementary RNA was prepared from each sample and hybridized to Affymetrix Human 133A oligonucleotide arrays which allowed the analysis of CD200 gene expression. In approximately 43% of AML patients, CD200 had a 'present' Affymetrix call (CD200 present ) with the remainder giving an absent call (CD200 absent ). CD200 present calls were highly correlated with abnormalities affecting CBF (24/28 vs 56/156, P ¼ 0.0001). There was no evidence of any association with age at diagnosis (mean ages: present 49 years vs absent 50 years, P ¼ 0.7), WBC (P ¼ 0.3) or sex (P ¼ 0.6), however, larger numbers of patients will be required to provide more reliable evidence and allow for adjustment of clinical and demographic parameters. Despite the association of CD200 expression with these good risk subtypes, analyses of survival stratified for CBF abnormalities showed that CD200 was significantly associated with worse survival (HR 1.68, 95% CI 1.08-2.62, P ¼ 0.02; Figure 1a and b). 
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